Change in neurocognitive performance among patients with non-Hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy
The success of chimeric antigen receptor (CAR) T cell therapy in treating patients with
relapsed/refractory hematologic malignancies is leading to a growing number of survivors
treated with this regimen. To our knowledge, no previous studies have examined
neurocognitive performance in adult CAR T cell therapy recipients, despite high rates of
neurotoxicity and cytokine release syndrome (CRS) in the acute treatment period. This study
examined changes in neurocognitive performance in the first year after CAR T cell therapy …
relapsed/refractory hematologic malignancies is leading to a growing number of survivors
treated with this regimen. To our knowledge, no previous studies have examined
neurocognitive performance in adult CAR T cell therapy recipients, despite high rates of
neurotoxicity and cytokine release syndrome (CRS) in the acute treatment period. This study
examined changes in neurocognitive performance in the first year after CAR T cell therapy …
以上显示的是最相近的搜索结果。 查看全部搜索结果